JP2008545808A - 血小板凝集阻害薬を含むナノ粒子状および制御放出組成物 - Google Patents

血小板凝集阻害薬を含むナノ粒子状および制御放出組成物 Download PDF

Info

Publication number
JP2008545808A
JP2008545808A JP2008533328A JP2008533328A JP2008545808A JP 2008545808 A JP2008545808 A JP 2008545808A JP 2008533328 A JP2008533328 A JP 2008533328A JP 2008533328 A JP2008533328 A JP 2008533328A JP 2008545808 A JP2008545808 A JP 2008545808A
Authority
JP
Japan
Prior art keywords
composition
less
platelet aggregation
aggregation inhibitor
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008533328A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008545808A5 (enExample
Inventor
ジェンキンス，スコット
リバーシッジ，ギャリー
スターク，ポール
ディヴェイン，ジョン・ジー
ファニング，ニオール
レクヒ，ガーヴィンダー・シング
Original Assignee
エラン・ファルマ・インターナショナル・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エラン・ファルマ・インターナショナル・リミテッド filed Critical エラン・ファルマ・インターナショナル・リミテッド
Publication of JP2008545808A publication Critical patent/JP2008545808A/ja
Publication of JP2008545808A5 publication Critical patent/JP2008545808A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2008533328A 2005-05-23 2006-05-23 血小板凝集阻害薬を含むナノ粒子状および制御放出組成物 Pending JP2008545808A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68362005P 2005-05-23 2005-05-23
PCT/US2006/019905 WO2008030209A2 (en) 2005-05-23 2006-05-23 Nanoparticulate and controlled release compositions comprising a platelet aggregation inhibitor

Publications (2)

Publication Number Publication Date
JP2008545808A true JP2008545808A (ja) 2008-12-18
JP2008545808A5 JP2008545808A5 (enExample) 2009-07-16

Family

ID=39153748

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008533328A Pending JP2008545808A (ja) 2005-05-23 2006-05-23 血小板凝集阻害薬を含むナノ粒子状および制御放出組成物

Country Status (12)

Country Link
US (1) US20090297596A1 (enExample)
EP (1) EP1937218A2 (enExample)
JP (1) JP2008545808A (enExample)
KR (1) KR20080047509A (enExample)
CN (1) CN101287451A (enExample)
BR (1) BRPI0609982A2 (enExample)
CA (1) CA2611506A1 (enExample)
EA (1) EA200702595A1 (enExample)
IL (1) IL187567A0 (enExample)
NO (1) NO20076588L (enExample)
WO (1) WO2008030209A2 (enExample)
ZA (1) ZA200710000B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013187075A1 (ja) * 2012-06-15 2013-12-19 公益財団法人先端医療振興財団 軽度認知障害の予防および／または治療剤

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9775819B2 (en) 2009-09-16 2017-10-03 R.P. Scherer Technologies, Llc Oral solid dosage form containing nanoparticles and process of formulating the same using fish gelatin
US8779146B2 (en) 2010-04-28 2014-07-15 Nuformix Limited Cilostazol cocrystals and compositions
US9012511B2 (en) 2010-05-19 2015-04-21 Alkermes Pharma Ireland Limited Nanoparticulate cinacalcet compositions
KR101282847B1 (ko) * 2011-07-27 2013-07-05 조선대학교산학협력단 실로스타졸을 함유하는 고체분산체 및 이를 포함하는 약학 조성물
TWI697337B (zh) 2013-08-07 2020-07-01 學校法人近畿大學 奈米粒子或奈米粒子組成物之製造方法，及支架或球囊導管之製造方法
CN103980326A (zh) * 2014-05-05 2014-08-13 珀莱雅化妆品股份有限公司 一种超临界co2反胶束萃取红景天苷的制备方法
KR101869406B1 (ko) * 2015-11-25 2018-07-24 한국유나이티드제약 주식회사 방출제어형 경질캡슐 제제
CN112592379B (zh) * 2020-12-18 2021-11-16 广东药科大学 一种β-D-葡萄糖短链脂肪酸酯化合物及其制备方法和应用
CN114796217B (zh) * 2021-01-29 2025-01-24 南京宁丹新药技术有限公司 一种含有西洛他唑的组合物在制备治疗脑血管病药物中的应用
CN117982677B (zh) * 2024-02-05 2025-09-09 沈阳药科大学 背载血小板激活抑制剂纳米粒的工程化血小板及其制备方法及应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04295420A (ja) * 1991-01-25 1992-10-20 Sterling Winthrop Inc 表面変性薬物微小粒子
JPH08501073A (ja) * 1992-06-10 1996-02-06 イーストマン コダック カンパニー 表面改質ｎｓａｉｄナノ粒子
WO2001023000A1 (fr) * 1999-09-30 2001-04-05 Otsuka Pharmaceutical Company, Limited Preparations d'enrobage solubles dans le tube digestif inferieur
JP2001163769A (ja) * 1999-03-25 2001-06-19 Otsuka Pharmaceut Co Ltd シロスタゾール製剤
JP2002528485A (ja) * 1998-11-02 2002-09-03 チャーチ、 マリア ジェイ． 多粒子改質放出組成物
JP2004520443A (ja) * 2000-11-20 2004-07-08 エラン ファーマ インターナショナル，リミティド 表面安定剤として共重合体を含むナノ粒子組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6117455A (en) * 1994-09-30 2000-09-12 Takeda Chemical Industries, Ltd. Sustained-release microcapsule of amorphous water-soluble pharmaceutical active agent
US6143211A (en) * 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
US6495579B1 (en) * 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
EG23951A (en) * 1999-03-25 2008-01-29 Otsuka Pharma Co Ltd Cilostazol preparation
CA2400172C (en) * 2000-02-28 2010-04-20 Genesegues, Inc. Nanocapsule encapsulation system and method
US6573382B2 (en) * 2001-06-29 2003-06-03 Grayson Walker Stowell Polymorphic forms of 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone
CA2456806C (en) * 2001-08-08 2011-10-18 Brown University Research Foundation Methods for micronization of hydrophobic drugs
TW200301135A (en) * 2001-12-27 2003-07-01 Otsuka Maryland Res Inst Inc Pharmaceutical compositions comprising a multifunctional phosphodiesterase inhibitor and an adenosine uptake inhibitor
US8512727B2 (en) * 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
CA2534924A1 (en) * 2003-08-08 2005-02-24 Elan Pharma International Ltd. Novel metaxalone compositions
US20050255155A1 (en) * 2004-05-11 2005-11-17 Glenmark Pharmaceuticals Limited Modified release cilostazol compositions
AU2006336417A1 (en) * 2005-05-10 2007-08-02 Elan Pharma International, Limited Nanoparticulate clopidogrel formulations
US20070003615A1 (en) * 2005-06-13 2007-01-04 Elan Pharma International Limited Nanoparticulate clopidogrel and aspirin combination formulations

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04295420A (ja) * 1991-01-25 1992-10-20 Sterling Winthrop Inc 表面変性薬物微小粒子
JPH08501073A (ja) * 1992-06-10 1996-02-06 イーストマン コダック カンパニー 表面改質ｎｓａｉｄナノ粒子
JP2002528485A (ja) * 1998-11-02 2002-09-03 チャーチ、 マリア ジェイ． 多粒子改質放出組成物
JP2001163769A (ja) * 1999-03-25 2001-06-19 Otsuka Pharmaceut Co Ltd シロスタゾール製剤
WO2001023000A1 (fr) * 1999-09-30 2001-04-05 Otsuka Pharmaceutical Company, Limited Preparations d'enrobage solubles dans le tube digestif inferieur
JP2004520443A (ja) * 2000-11-20 2004-07-08 エラン ファーマ インターナショナル，リミティド 表面安定剤として共重合体を含むナノ粒子組成物

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013187075A1 (ja) * 2012-06-15 2013-12-19 公益財団法人先端医療振興財団 軽度認知障害の予防および／または治療剤
US9737524B2 (en) 2012-06-15 2017-08-22 Foundation For Biomedical Research And Innovation Prophylactic and/or therapeutic agent for mild cognitive impairment
US10016409B2 (en) 2012-06-15 2018-07-10 Foundation For Biomedical Research And Innovation At Kobe Method for improving interstitial flow

Also Published As

Publication number Publication date
BRPI0609982A2 (pt) 2010-05-18
KR20080047509A (ko) 2008-05-29
IL187567A0 (en) 2011-08-01
WO2008030209A2 (en) 2008-03-13
CN101287451A (zh) 2008-10-15
WO2008030209A3 (en) 2008-07-03
US20090297596A1 (en) 2009-12-03
ZA200710000B (en) 2009-12-30
CA2611506A1 (en) 2006-11-23
EP1937218A2 (en) 2008-07-02
EA200702595A1 (ru) 2008-12-30
NO20076588L (no) 2008-02-20

Similar Documents

Publication Publication Date Title
US8119163B2 (en) Nanoparticulate and controlled release compositions comprising cefditoren
JP2009541360A (ja) ナノ粒子状メロキシカムおよび制御放出ヒドロコドンを含む組成物
MX2008015275A (es) Formulaciones de posaconazol en nanoparticulas.
JP2008535921A (ja) シクロスポリンを含むナノ粒子および放出調節された組成物
JP2009541359A (ja) ナノ粒子状ナプロキセンおよび制御放出ヒドロコドンを含む組成物
US20080317843A1 (en) Nanoparticulate formulations of modafinil
JP2008545808A (ja) 血小板凝集阻害薬を含むナノ粒子状および制御放出組成物
US20110064803A1 (en) Nanoparticulate and controlled release compositions comprising vitamin k2
JP2008540691A (ja) セファロスポリンを含むナノ粒子および放出制御組成物
JP2010521494A (ja) 麻薬性および非麻薬性鎮痛剤の組み合わせ
JP2008536856A (ja) プロスタグランジン誘導体を含んでなるナノ粒子状且つ徐放性の組成物
KR20080024206A (ko) 아릴-헤테로시클릭 화합물을 함유하는 나노입자형 조절방출 조성물
JP2009517485A (ja) セフジトレンを含むナノ粒子状および制御放出組成物
WO2007070082A1 (en) Nanoparticulate and controlled release compositions comprising teprenone
US20100247636A1 (en) Nanoparticulate and controlled release compositions comprising nilvadipine
JP2008546781A (ja) アリール−複素環式化合物を含んでなるナノ粒状及び制御放出の組成物
AU2006343445B8 (en) Nanoparticulate and controlled release compositions comprising a platelet aggregation inhibitor
WO2007106111A2 (en) Nanoparticulate and controlled release compositions comprising nilvadipine
MX2007014764A (en) Nanoparticulate and controlled release compositions comprising a platelet aggregation inhibitor
JP2008540550A (ja) ビタミンｋ２を含むナノ粒子および制御放出組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090525

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090525

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20110915

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120312

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120611

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120618

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121022